                         SEQUENCE LISTING

<110>  NANJING LEGEND BIOTECH CO., LTD.
 
<120>  METHODS AND COMPOSITIONS FOR DEPLETING NATURAL KILLER CELLS AND 
       USES THEREOF IN CELLULAR THERAPIES

<130>  L2-W20245WO

<140>
<141>

<150>  PCT/CN2020/136157
<151>  2020-12-14

<160>  65    

<170>  PatentIn version 3.5

<210>  1
<211>  122
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH of Daratumumab (anti-CD38 antibody)

<400>  1

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Phe Thr Phe Asn Ser Phe 
            20                  25                  30          


Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ser Ala Ile Ser Gly Ser Gly Gly Gly Thr Tyr Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Phe Cys 
                85                  90                  95      


Ala Lys Asp Lys Ile Leu Trp Phe Gly Glu Pro Val Phe Asp Tyr Trp 
            100                 105                 110         


Gly Gln Gly Thr Leu Val Thr Val Ser Ser 
        115                 120         


<210>  2
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL of Daratumumab (anti-CD38 antibody)

<400>  2

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Pro 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  3
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH of Isatuximab (anti-CD38 antibody)

<400>  3

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Ala Lys Pro Gly Thr 
1               5                   10                  15      


Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 
            20                  25                  30          


Trp Met Gln Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Thr Ile Tyr Pro Gly Asp Gly Asp Thr Gly Tyr Ala Gln Lys Phe 
    50                  55                  60                  


Gln Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Lys Thr Val Tyr 
65                  70                  75                  80  


Met His Leu Ser Ser Leu Ala Ser Glu Asp Ser Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Gly Asp Tyr Tyr Gly Ser Asn Ser Leu Asp Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Ser Val Thr Val Ser Ser 
        115                 120 


<210>  4
<211>  109
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL of Isatuximab (anti-CD38 antibody)

<400>  4

Asp Ile Val Met Thr Gln Ser His Leu Ser Met Ser Thr Ser Leu Gly 
1               5                   10                  15      


Asp Pro Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Ser Thr Val 
            20                  25                  30          


Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Arg Arg Leu Ile 
        35                  40                  45              


Tyr Ser Ala Ser Tyr Arg Tyr Ile Gly Val Pro Asp Arg Phe Thr Gly 
    50                  55                  60                  


Ser Gly Ala Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Val Gln Ala 
65                  70                  75                  80  


Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln His Tyr Ser Pro Pro Tyr 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Thr 
            100                 105                 


<210>  5
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH of elotuzumab (anti-CS1 antibody)

<400>  5

Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly 
1               5                   10                  15      


Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asp Phe Ser Arg 
            20                  25                  30          


Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp 
        35                  40                  45              


Ile Gly Glu Ile Asn Pro Asp Ser Ser Thr Ile Asn Tyr Ala Pro Ser 
    50                  55                  60                  


Leu Lys Asp Lys Phe Ile Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu 
65                  70                  75                  80  


Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr 
                85                  90                  95      


Cys Ala Arg Pro Asp Gly Asn Tyr Trp Tyr Phe Asp Val Trp Gly Gln 
            100                 105                 110         


Gly Thr Leu Val Thr Val Ser Ser 
        115                 120 


<210>  6
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL of elotuzumab (anti-CS1 antibody)

<400>  6

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Val Gly Ile Ala 
            20                  25                  30          


Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Val Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Trp Ala Ser Thr Arg His Thr Gly Val Pro Asp Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Val Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Ser Tyr Pro Tyr 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  7
<211>  118
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-BCMA1 sdAb

<400>  7

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Thr Met Gly 
            20                  25                  30          


Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Ala Ile 
        35                  40                  45              


Ser Leu Ser Pro Thr Leu Ala Tyr Tyr Ala Glu Ser Val Lys Gly Arg 
    50                  55                  60                  


Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Val Leu Gln Met 
65                  70                  75                  80  


Asn Ser Leu Lys Pro Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Ala Asp 
                85                  90                  95      


Arg Lys Ser Val Met Ser Ile Arg Pro Asp Tyr Trp Gly Gln Gly Thr 
            100                 105                 110         


Gln Val Thr Val Ser Ser 
        115             


<210>  8
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-BCMA2 sdAb

<400>  8

Gln Val Gln Leu Glu Glu Ser Gly Gly Gly Ser Val Gln Ala Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Tyr Thr Tyr Ser Thr Tyr Ser Asn Tyr 
            20                  25                  30          


Tyr Met Gly Trp Phe Arg Glu Ala Pro Gly Lys Ala Arg Thr Ser Val 
        35                  40                  45              


Ala Ile Ile Ser Ser Asp Thr Thr Ile Thr Tyr Lys Asp Ala Val Lys 
    50                  55                  60                  


Gly Arg Phe Thr Ile Ser Lys Asp Asn Ala Lys Asn Thr Leu Tyr Leu 
65                  70                  75                  80  


Gln Met Asn Ser Leu Lys Pro Glu Asp Ser Ala Met Tyr Arg Cys Ala 
                85                  90                  95      


Ala Trp Thr Ser Asp Trp Ser Val Ala Tyr Trp Gly Gln Gly Thr Gln 
            100                 105                 110         


Val Thr Val Ser Ser 
        115         


<210>  9
<211>  119
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-BCMA3 sdAb

<400>  9

Ala Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Asp 
1               5                   10                  15      


Ser Leu Arg Leu Thr Cys Thr Ala Ser Gly Arg Ala Phe Ser Thr Tyr 
            20                  25                  30          


Phe Met Ala Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 
        35                  40                  45              


Ala Gly Ile Ala Trp Ser Gly Gly Ser Thr Ala Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Lys Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Ser Arg Gly Ile Glu Val Glu Glu Phe Gly Ala Trp Gly Gln Gly 
            100                 105                 110         


Thr Gln Val Thr Val Ser Ser 
        115                 


<210>  10
<211>  256
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  K5 (HHV8P)

<400>  10

Met Ala Ser Lys Asp Val Glu Glu Gly Val Glu Gly Pro Ile Cys Trp 
1               5                   10                  15      


Ile Cys Arg Glu Glu Val Gly Asn Glu Gly Ile His Pro Cys Ala Cys 
            20                  25                  30          


Thr Gly Glu Leu Asp Val Val His Pro Gln Cys Leu Ser Thr Trp Leu 
        35                  40                  45              


Thr Val Ser Arg Asn Thr Ala Cys Gln Met Cys Arg Val Ile Tyr Arg 
    50                  55                  60                  


Thr Arg Thr Gln Trp Arg Ser Arg Leu Asn Leu Trp Pro Glu Met Glu 
65                  70                  75                  80  


Arg Gln Glu Ile Phe Glu Leu Phe Leu Leu Met Ser Val Val Val Ala 
                85                  90                  95      


Gly Leu Val Gly Val Ala Leu Cys Thr Trp Thr Leu Leu Val Ile Leu 
            100                 105                 110         


Thr Ala Pro Ala Gly Thr Phe Ser Pro Gly Ala Val Leu Gly Phe Leu 
        115                 120                 125             


Cys Phe Phe Gly Phe Tyr Gln Ile Phe Ile Val Phe Ala Phe Gly Gly 
    130                 135                 140                 


Ile Cys Arg Val Ser Gly Thr Val Arg Ala Leu Tyr Ala Ala Asn Asn 
145                 150                 155                 160 


Thr Arg Val Thr Val Leu Pro Tyr Arg Arg Pro Arg Arg Pro Thr Ala 
                165                 170                 175     


Asn Glu Asp Asn Ile Glu Leu Thr Val Leu Val Gly Pro Ala Gly Gly 
            180                 185                 190         


Thr Asp Glu Glu Pro Thr Asp Glu Ser Ser Glu Gly Asp Val Ala Ser 
        195                 200                 205             


Gly Asp Lys Glu Arg Asp Gly Ser Ser Gly Asp Glu Pro Asp Gly Gly 
    210                 215                 220                 


Pro Asn Asp Arg Ala Gly Leu Arg Gly Thr Ala Arg Thr Asp Leu Cys 
225                 230                 235                 240 


Ala Pro Thr Lys Lys Pro Val Arg Lys Asn His Pro Lys Asn Asn Gly 
                245                 250                 255     


<210>  11
<211>  183
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  US6 (HHV-5)

<400>  11

Met Asp Leu Leu Ile Arg Leu Gly Phe Leu Leu Met Cys Ala Leu Pro 
1               5                   10                  15      


Thr Pro Gly Glu Arg Ser Ser Arg Asp Pro Lys Thr Leu Leu Ser Leu 
            20                  25                  30          


Ser Pro Arg Gln Gln Ala Cys Val Pro Arg Thr Lys Ser His Arg Pro 
        35                  40                  45              


Val Cys Tyr Asn Asp Thr Gly Asp Cys Thr Asp Ala Asp Asp Ser Trp 
    50                  55                  60                  


Lys Gln Leu Gly Glu Asp Phe Ala His Gln Cys Leu Gln Ala Ala Lys 
65                  70                  75                  80  


Lys Arg Pro Lys Thr His Lys Ser Arg Pro Asn Asp Arg Asn Leu Glu 
                85                  90                  95      


Gly Arg Leu Thr Cys Gln Arg Val Arg Arg Leu Leu Pro Cys Asp Leu 
            100                 105                 110         


Asp Ile His Pro Ser His Arg Leu Leu Thr Leu Met Asn Asn Cys Val 
        115                 120                 125             


Cys Asp Gly Ala Val Trp Asn Ala Phe Arg Leu Ile Glu Arg His Gly 
    130                 135                 140                 


Phe Phe Ala Val Thr Leu Tyr Leu Cys Cys Gly Ile Thr Leu Leu Val 
145                 150                 155                 160 


Val Ile Leu Ala Leu Leu Cys Ser Ile Thr Tyr Glu Ser Thr Gly Arg 
                165                 170                 175     


Gly Ile Arg Arg Cys Gly Ser 
            180             


<210>  12
<211>  88
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  ICP47 (HHV-1)

<400>  12

Met Ser Trp Ala Leu Glu Met Ala Asp Thr Phe Leu Asp Thr Met Arg 
1               5                   10                  15      


Val Gly Pro Arg Thr Tyr Ala Asp Val Arg Asp Glu Ile Asn Lys Arg 
            20                  25                  30          


Gly Arg Glu Asp Arg Glu Ala Ala Arg Thr Ala Val His Asp Pro Glu 
        35                  40                  45              


Arg Pro Leu Leu Arg Ser Pro Gly Leu Leu Pro Glu Ile Ala Pro Asn 
    50                  55                  60                  


Ala Ser Leu Gly Val Ala His Arg Arg Thr Gly Gly Thr Val Thr Asp 
65                  70                  75                  80  


Ser Pro Arg Asn Pro Val Thr Arg 
                85              


<210>  13
<211>  78
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  sICP47 of CeHV-16

<400>  13

Met Ser Ser Leu Tyr Leu Ala Glu Val Asp Ala Phe Leu Gln Ser Pro 
1               5                   10                  15      


Arg Thr Arg His Arg Thr Cys Ala Asp Leu Arg Arg Glu Leu Asp Ala 
            20                  25                  30          


Tyr Ala Asp Glu Glu Arg Arg Glu Ala Ala Lys Ala Ile Ala His Pro 
        35                  40                  45              


Asp Arg Pro Leu Leu Ala Pro Pro Ser Ala Pro Pro Asp Arg Ser Arg 
    50                  55                  60                  


Pro Ala Pro Arg Gly Thr Ala His Pro Pro Ala Ala Ser Pro 
65                  70                  75              


<210>  14
<211>  81
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  sICP47 of CeHV-1

<400>  14

Met Ser Ser Arg Tyr Leu Ala Ala Val Asp Asp Tyr Leu His His Pro 
1               5                   10                  15      


Ser Pro Arg Tyr Gln Ala His Val Asp Leu Arg Arg Glu Leu Arg Ala 
            20                  25                  30          


Tyr Ala Asp Glu Glu Arg Arg Glu Ala Ala Arg Ala Ile Ala His Pro 
        35                  40                  45              


Glu Arg Pro Leu Leu Pro Pro Pro Ala Thr Gln Ala Ala Pro Pro Gln 
    50                  55                  60                  


Pro Ser Thr Arg Glu Ala Ala His Pro Ser Ala Pro Thr Ala Ala Ser 
65                  70                  75                  80  


Ser 
    


<210>  15
<211>  78
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  sICP47 of SA8

<400>  15

Met Ser Ser Leu Tyr Leu Ala Thr Val Asp Ala Phe Leu Arg Asn Pro 
1               5                   10                  15      


His Thr Arg His Arg Thr Cys Ala Asp Leu Arg Arg Glu Leu Asp Ala 
            20                  25                  30          


Tyr Ala Asp Glu Glu Arg Arg Glu Ala Ala Lys Ala Ile Ala His Pro 
        35                  40                  45              


Asp Arg Pro Leu Leu Ala Pro Pro Ser Ala Pro Pro Asn His Ser His 
    50                  55                  60                  


Leu Ala Ala Arg Glu Thr Ala Pro Pro Pro Ala Ala Thr Pro 
65                  70                  75              


<210>  16
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GS linker1

<400>  16

Gly Gly Gly Gly Ser 
1               5   


<210>  17
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GS linker2

<400>  17

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 
1               5                   10  


<210>  18
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GS linker3

<400>  18

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 
1               5                   10                  15  


<210>  19
<211>  21
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CD8a leading peptide

<400>  19

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu 
1               5                   10                  15      


His Ala Ala Arg Pro 
            20      


<210>  20
<211>  45
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CD8a hinge

<400>  20

Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala 
1               5                   10                  15      


Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly 
            20                  25                  30          


Gly Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp 
        35                  40                  45  


<210>  21
<211>  24
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CD8a transmembrane

<400>  21

Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu 
1               5                   10                  15      


Ser Leu Val Ile Thr Leu Tyr Cys 
            20                  


<210>  22
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CD4 leading peptide

<400>  22

Met Asn Arg Gly Val Pro Phe Arg His Leu Leu Leu Val Leu Gln Leu 
1               5                   10                  15      


Ala Leu Leu Pro Ala Ala Thr Gln Gly 
            20                  25  


<210>  23
<211>  44
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CD4 transmembrane

<400>  23

Ser Gly Gln Val Leu Leu Glu Ser Asn Ile Lys Val Leu Pro Thr Trp 
1               5                   10                  15      


Ser Thr Pro Val Gln Pro Met Ala Leu Ile Val Leu Gly Gly Val Ala 
            20                  25                  30          


Gly Leu Leu Leu Phe Ile Gly Leu Gly Ile Phe Phe 
        35                  40                  


<210>  24
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  intracellular domain of CD3 zeta

<400>  24

Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly 
1               5                   10                  15      


Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr 
            20                  25                  30          


Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys 
        35                  40                  45              


Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys 
    50                  55                  60                  


Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg 
65                  70                  75                  80  


Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala 
                85                  90                  95      


Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg 
            100                 105                 110         


<210>  25
<211>  42
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  intracellular domain of 4-1BB

<400>  25

Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met 
1               5                   10                  15      


Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe 
            20                  25                  30          


Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu 
        35                  40          


<210>  26
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CD3 epsilon leading peptide

<400>  26

Met Gln Ser Gly Thr His Trp Arg Val Leu Gly Leu Cys Leu Leu Ser 
1               5                   10                  15      


Val Gly Val Trp Gly Gln 
            20          


<210>  27
<211>  185
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CD3 epsilon

<400>  27

Asp Gly Asn Glu Glu Met Gly Gly Ile Thr Gln Thr Pro Tyr Lys Val 
1               5                   10                  15      


Ser Ile Ser Gly Thr Thr Val Ile Leu Thr Cys Pro Gln Tyr Pro Gly 
            20                  25                  30          


Ser Glu Ile Leu Trp Gln His Asn Asp Lys Asn Ile Gly Gly Asp Glu 
        35                  40                  45              


Asp Asp Lys Asn Ile Gly Ser Asp Glu Asp His Leu Ser Leu Lys Glu 
    50                  55                  60                  


Phe Ser Glu Leu Glu Gln Ser Gly Tyr Tyr Val Cys Tyr Pro Arg Gly 
65                  70                  75                  80  


Ser Lys Pro Glu Asp Ala Asn Phe Tyr Leu Tyr Leu Arg Ala Arg Val 
                85                  90                  95      


Cys Glu Asn Cys Met Glu Met Asp Val Met Ser Val Ala Thr Ile Val 
            100                 105                 110         


Ile Val Asp Ile Cys Ile Thr Gly Gly Leu Leu Leu Leu Val Tyr Tyr 
        115                 120                 125             


Trp Ser Lys Asn Arg Lys Ala Lys Ala Lys Pro Val Thr Arg Gly Ala 
    130                 135                 140                 


Gly Ala Gly Gly Arg Gln Arg Gly Gln Asn Lys Glu Arg Pro Pro Pro 
145                 150                 155                 160 


Val Pro Asn Pro Asp Tyr Glu Pro Ile Arg Lys Gly Gln Arg Asp Leu 
                165                 170                 175     


Tyr Ser Gly Leu Asn Gln Arg Arg Ile 
            180                 185 


<210>  28
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH of anti-IL-T2 antibody

<400>  28

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Arg Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ala His 
            20                  25                  30          


Thr Ile His Trp Val Lys Gln Arg Ser Gly Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Trp Leu Tyr Pro Gly Ser Gly Ser Ile Lys Tyr Asn Glu Lys Phe 
    50                  55                  60                  


Lys Asp Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Val Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Arg Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 
                85                  90                  95      


Ala Arg His Thr Asn Trp Asp Phe Asp Tyr Trp Gly Gln Gly Thr Thr 
            100                 105                 110         


Leu Thr Val Ser Ser 
        115         


<210>  29
<211>  111
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL of anti-IL-T2 antibody

<400>  29

Asn Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly 
1               5                   10                  15      


Gln Arg Ala Thr Ile Ser Cys Lys Ala Ser Gln Ser Val Asp Tyr Gly 
            20                  25                  30          


Gly Ala Ser Tyr Met Asn Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro 
        35                  40                  45              


Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Glu Ser Gly Ile Pro Ala 
    50                  55                  60                  


Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Leu Thr Leu Asn Ile His 
65                  70                  75                  80  


Pro Val Glu Glu Glu Asp Ala Ala Met Tyr Tyr Cys Gln Gln Ser Asn 
                85                  90                  95      


Glu Glu Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110     


<210>  30
<211>  116
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH of anti-CD137 antibody

<400>  30

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu 
1               5                   10                  15      


Ser Leu Arg Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Ser Thr Tyr 
            20                  25                  30          


Trp Ile Ser Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Lys Ile Tyr Pro Gly Asp Ser Tyr Thr Asn Tyr Ser Pro Ser Phe 
    50                  55                  60                  


Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Gly Tyr Gly Ile Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val 
            100                 105                 110         


Thr Val Ser Ser 
        115     


<210>  31
<211>  108
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL of anti-CD137 antibody

<400>  31

Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln 
1               5                   10                  15      


Thr Ala Ser Ile Thr Cys Ser Gly Asp Asn Ile Gly Asp Gln Tyr Ala 
            20                  25                  30          


His Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr 
        35                  40                  45              


Gln Asp Lys Asn Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser 
    50                  55                  60                  


Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Met 
65                  70                  75                  80  


Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Tyr Thr Gly Phe Gly Ser Leu 
                85                  90                  95      


Ala Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 
            100                 105             


<210>  32
<211>  125
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH of anti-NKG2A antibody

<400>  32

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 
            20                  25                  30          


Trp Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Asp Pro Tyr Asp Ser Glu Thr His Tyr Ala Gln Lys Leu 
    50                  55                  60                  


Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Gly Gly Tyr Asp Phe Asp Val Gly Thr Leu Tyr Trp Phe Phe 
            100                 105                 110         


Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
        115                 120                 125 


<210>  33
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL of anti-NKG2A antibody

<400>  33

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Glu Asn Ile Tyr Ser Tyr 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Asn Ala Lys Thr Leu Ala Glu Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Gln His His Tyr Gly Thr Pro Arg 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  34
<211>  115
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH of anti-NKG2D-1 antibody

<400>  34

Gln Val His Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Thr Val Ser Asp Asp Ser Ile Ser Ser Tyr 
            20                  25                  30          


Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly His Ile Ser Tyr Ser Gly Ser Ala Asn Tyr Asn Pro Ser Leu Lys 
    50                  55                  60                  


Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 
65                  70                  75                  80  


Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 
                85                  90                  95      


Asn Trp Asp Asp Ala Phe Asn Ile Trp Gly Gln Gly Thr Met Val Thr 
            100                 105                 110         


Val Ser Ser 
        115 


<210>  35
<211>  108
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL of anti-NKG2D-1 antibody

<400>  35

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser 
            20                  25                  30          


Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 
        35                  40                  45              


Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 
    50                  55                  60                  


Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 
65                  70                  75                  80  


Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 
                85                  90                  95      


Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
            100                 105             


<210>  36
<211>  123
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH of anti-NKG2D-2 antibody

<400>  36

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Glu Pro Gly Glu 
1               5                   10                  15      


Ser Leu Lys Ile Ser Cys Lys Asn Ser Gly Tyr Ser Phe Thr Asn Tyr 
            20                  25                  30          


Trp Val Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe 
    50                  55                  60                  


Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Asn Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys 
                85                  90                  95      


Gly Arg Leu Thr Met Phe Arg Gly Ile Ile Ile Gly Tyr Phe Asp Tyr 
            100                 105                 110         


Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 
        115                 120             


<210>  37
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL of anti-NKG2D-2 antibody

<400>  37

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Trp 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  38
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH of anti-CD16 antibody

<400>  38

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Arg Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr 
            20                  25                  30          


Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ser Gly Ile Asn Trp Asn Gly Gly Ser Thr Gly Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Gly Arg Ser Leu Leu Phe Asp Tyr Trp Gly Gln Gly Thr Leu 
            100                 105                 110         


Val Thr Val Ser Arg 
        115         


<210>  39
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL of anti-CD16 antibody

<400>  39

Ser Glu Leu Thr Gln Asp Pro Ala Val Ser Val Ala Leu Gly Gln Thr 
1               5                   10                  15      


Val Arg Ile Thr Cys Gln Gly Asp Ser Leu Arg Ser Tyr Tyr Ala Ser 
            20                  25                  30          


Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr Gly 
        35                  40                  45              


Lys Asn Asn Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Ser 
    50                  55                  60                  


Ser Gly Asn Thr Ala Ser Leu Thr Ile Thr Gly Ala Gln Ala Glu Asp 
65                  70                  75                  80  


Glu Ala Asp Tyr Tyr Cys Asn Ser Arg Asp Ser Ser Gly Asn His Val 
                85                  90                  95      


Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 
            100                 105         


<210>  40
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH of anti-CD16a antibody

<400>  40

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu 
1               5                   10                  15      


Ser Leu Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 
            20                  25                  30          


Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys Phe 
    50                  55                  60                  


Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Gly Ser Ala Tyr Tyr Tyr Asp Phe Ala Asp Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Leu Val Thr Val Ser Ser 
        115                 120 


<210>  41
<211>  106
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL of anti-CD16a antibody

<400>  41

Ser Tyr Val Leu Thr Gln Pro Ser Ser Val Ser Val Ala Pro Gly Gln 
1               5                   10                  15      


Thr Ala Thr Ile Ser Cys Gly Gly His Asn Ile Gly Ser Lys Asn Val 
            20                  25                  30          


His Trp Tyr Gln Gln Arg Pro Gly Gln Ser Pro Val Leu Val Ile Tyr 
        35                  40                  45              


Gln Asp Asn Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser 
    50                  55                  60                  


Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Met 
65                  70                  75                  80  


Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Asn Tyr Ser Val Leu 
                85                  90                  95      


Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 
            100                 105     


<210>  42
<211>  118
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH of anti-KIR antibody

<400>  42

Gln Ile Gln Leu Val Gln Ser Gly Ser Glu Leu Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Ala 
            20                  25                  30          


Gly Met Gln Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Trp Ile Asn Ser His Ser Gly Val Pro Lys Tyr Ala Glu Asp Phe 
    50                  55                  60                  


Lys Gly Arg Phe Val Phe Ser Leu Asp Thr Ser Val Ser Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Ile Ser Ser Leu Lys Ala Glu Asp Thr Ala Val Tyr Phe Cys 
                85                  90                  95      


Ala Arg Gly Gly Asp Glu Gly Val Met Asp Tyr Trp Gly Gln Gly Thr 
            100                 105                 110         


Thr Val Thr Val Ser Ser 
        115             


<210>  43
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL of anti-KIR antibody

<400>  43

Asp Ile Gln Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Val Ser Thr Ala 
            20                  25                  30          


Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Trp Thr Ser Thr Arg His Thr Gly Val Pro Asp Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Ala 
65                  70                  75                  80  


Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln His Tyr Ser Thr Pro Trp 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  44
<211>  118
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH of anti-CD56 antibody

<400>  44

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe 
            20                  25                  30          


Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Tyr Ile Ser Ser Gly Ser Phe Thr Ile Tyr Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Met Arg Lys Gly Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr 
            100                 105                 110         


Leu Val Thr Val Ser Ser 
        115             


<210>  45
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL of anti-CD56 antibody

<400>  45

Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly 
1               5                   10                  15      


Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ile Ile Ile His Ser 
            20                  25                  30          


Asp Gly Asn Thr Tyr Leu Glu Trp Phe Gln Gln Arg Pro Gly Gln Ser 
        35                  40                  45              


Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Phe Gln Gly 
                85                  90                  95      


Ser His Val Pro His Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
            100                 105                 110         


<210>  46
<211>  121
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH of anti-CD226-1 antibody

<400>  46

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Asp Trp Val Thr Thr Gly Pro Phe Ala Phe Asp Leu Trp Gly 
            100                 105                 110         


Gln Gly Thr Met Val Thr Val Ser Ser 
        115                 120     


<210>  47
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL of anti-CD226-1 antibody

<400>  47

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr 
            20                  25                  30          


Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Tyr Thr Leu Pro Phe 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  48
<211>  118
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH of anti-CD226-2 antibody

<400>  48

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Asp Ser Ser Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr 
            100                 105                 110         


Leu Val Thr Val Ser Ser 
        115             


<210>  49
<211>  108
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL of anti-CD226-2 antibody

<400>  49

Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser 
65                  70                  75                  80  


Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Lys Trp Pro Leu 
                85                  90                  95      


Phe Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
            100                 105             


<210>  50
<211>  116
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH of anti-CD25-1 antibody

<400>  50

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 
            20                  25                  30          


Arg Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Tyr Ile Asn Pro Ser Thr Gly Tyr Thr Glu Tyr Asn Gln Lys Phe 
    50                  55                  60                  


Lys Asp Lys Ala Thr Ile Thr Ala Asp Glu Ser Thr Asn Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Gly Gly Gly Val Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val 
            100                 105                 110         


Thr Val Ser Ser 
        115     


<210>  51
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL of anti-CD25-1 antibody

<400>  51

Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Ile Ser Tyr Met 
            20                  25                  30          


His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr 
        35                  40                  45              


Thr Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser 
    50                  55                  60                  


Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp 
65                  70                  75                  80  


Asp Phe Ala Thr Tyr Tyr Cys His Gln Arg Ser Thr Tyr Pro Leu Thr 
                85                  90                  95      


Phe Gly Gln Gly Thr Lys Val Glu Val Lys Arg 
            100                 105         


<210>  52
<211>  115
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH of anti-CD25-2 antibody

<400>  52

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Arg Tyr 
            20                  25                  30          


Ile Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Ile Pro Ile Leu Gly Val Glu Asn Tyr Ala Gln Lys Phe 
    50                  55                  60                  


Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Lys Asp Trp Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr 
            100                 105                 110         


Val Ser Ser 
        115 


<210>  53
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL of anti-CD25-2 antibody

<400>  53

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Leu 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  54
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH of anti-CD83 antibody

<400>  54

Gln Val Gln Leu Lys Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 
1               5                   10                  15      


Ser Leu Ser Leu Thr Cys Ser Val Thr Gly Phe Ser Ile Thr Thr Gly 
            20                  25                  30          


Gly Tyr Trp Trp Thr Trp Ile Arg Gln Phe Pro Gly Gln Lys Leu Glu 
        35                  40                  45              


Trp Met Gly Tyr Ile Phe Ser Ser Gly Asn Thr Asn Tyr Asn Pro Ser 
    50                  55                  60                  


Ile Lys Ser Arg Ile Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln Phe 
65                  70                  75                  80  


Phe Leu Gln Leu Asn Ser Val Thr Thr Glu Gly Asp Thr Ala Arg Tyr 
                85                  90                  95      


Tyr Cys Ala Arg Ala Tyr Gly Lys Leu Gly Phe Asp Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Leu Val Thr Val Ser Ser 
        115                 120 


<210>  55
<211>  111
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL of anti-CD83 antibody

<400>  55

Gln Pro Val Leu Thr Gln Ser Pro Ser Ala Ser Ala Ser Leu Gly Asn 
1               5                   10                  15      


Ser Val Lys Ile Thr Cys Thr Leu Ser Ser Gln His Ser Thr Tyr Thr 
            20                  25                  30          


Ile Gly Trp Tyr Gln Gln His Pro Asp Lys Ala Pro Lys Tyr Val Met 
        35                  40                  45              


Tyr Val Asn Ser Asp Gly Ser His Ser Lys Gly Asp Gly Ile Pro Asp 
    50                  55                  60                  


Arg Phe Ser Gly Ser Ser Ser Gly Ala His Arg Tyr Leu Ser Ile Ser 
65                  70                  75                  80  


Asn Ile Gln Pro Glu Asp Glu Ala Asp Tyr Phe Cys Gly Ser Ser Asp 
                85                  90                  95      


Ser Ser Gly Tyr Val Phe Gly Ser Gly Thr Gln Leu Thr Val Leu 
            100                 105                 110     


<210>  56
<211>  119
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH of anti-KLRG1 antibody

<400>  56

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp His 
            20                  25                  30          


Asn Met His Trp Val Lys Gln Ala Thr Gly Gln Gly Leu Glu Trp Phe 
        35                  40                  45              


Gly Phe Ile Asn Pro Asn Thr Gly Val Thr Arg Tyr Asn Gln Lys Phe 
    50                  55                  60                  


Gln Gly Arg Val Thr Leu Thr Ile Asn Lys Ala Ile Ser Thr Ala Tyr 
65                  70                  75                  80  


Leu Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Asp Tyr Tyr Gly Ser Ala Trp Phe Ala Tyr Trp Gly Gln Gly 
            100                 105                 110         


Thr Leu Val Thr Val Ser Ser 
        115                 


<210>  57
<211>  109
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL of anti-KLRG1 antibody

<400>  57

Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly 
1               5                   10                  15      


Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Thr Leu Leu Tyr Ser 
            20                  25                  30          


Ser Asp Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 
        35                  40                  45              


Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val 
    50                  55                  60                  


Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 
65                  70                  75                  80  


Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln 
                85                  90                  95      


Tyr Tyr Asn Tyr Pro Thr Phe Gly Gly Gly Thr Lys Val 
            100                 105                 


<210>  58
<211>  118
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH of anti-CD70 antibody

<400>  58

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 
            20                  25                  30          


Gly Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Lys Trp Met 
        35                  40                  45              


Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Ala Phe 
    50                  55                  60                  


Lys Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Asp Tyr Gly Asp Tyr Gly Met Asp Tyr Trp Gly Gln Gly Thr 
            100                 105                 110         


Thr Val Thr Val Ser Ser 
        115             


<210>  59
<211>  111
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL of anti-CD70 antibody

<400>  59

Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly 
1               5                   10                  15      


Glu Arg Ala Thr Ile Asn Cys Arg Ala Ser Lys Ser Val Ser Thr Ser 
            20                  25                  30          


Gly Tyr Ser Phe Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro 
        35                  40                  45              


Lys Leu Leu Ile Tyr Leu Ala Ser Asn Leu Glu Ser Gly Val Pro Asp 
    50                  55                  60                  


Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser 
65                  70                  75                  80  


Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln His Ser Arg 
                85                  90                  95      


Glu Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
            100                 105                 110     


<210>  60
<211>  160
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH of anti-CD30 antibody

<400>  60

Gln Ile Gln Leu Gln Gln Ser Gly Pro Glu Val Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 
            20                  25                  30          


Tyr Ile Thr Trp Val Lys Gln Lys Pro Gly Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Trp Ile Tyr Pro Gly Ser Gly Asn Thr Lys Tyr Asn Glu Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Val Asp Thr Ser Ser Ser Thr Ala Phe 
65                  70                  75                  80  


Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Phe Cys 
                85                  90                  95      


Ala Asn Tyr Gly Asn Tyr Trp Phe Ala Tyr Trp Gly Gln Gly Thr Gln 
            100                 105                 110         


Val Thr Val Ser Ala Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu 
        115                 120                 125             


Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys 
    130                 135                 140                 


Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser 
145                 150                 155                 160 


<210>  61
<211>  111
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL of anti-CD30 antibody

<400>  61

Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly 
1               5                   10                  15      


Gln Arg Ala Thr Ile Ser Cys Lys Ala Ser Gln Ser Val Asp Phe Asp 
            20                  25                  30          


Gly Asp Ser Tyr Met Asn Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro 
        35                  40                  45              


Lys Val Leu Ile Tyr Ala Ala Ser Asn Leu Glu Ser Gly Ile Pro Ala 
    50                  55                  60                  


Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His 
65                  70                  75                  80  


Pro Val Glu Glu Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Ser Asn 
                85                  90                  95      


Glu Asp Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110     


<210>  62
<211>  109
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH of anti-CD229 antibody

<400>  62

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Pro Val Ala Ser Gln Ser Ile Gly Ser 
            20                  25                  30          


Ser Leu His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Phe Leu 
        35                  40                  45              


Ile Tyr Asp Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Pro Val Phe 
    50                  55                  60                  


Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu 
65                  70                  75                  80  


Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr 
                85                  90                  95      


Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 


<210>  63
<211>  121
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL of anti-CD229 antibody

<400>  63

Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln 
1               5                   10                  15      


Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser 
            20                  25                  30          


Gly Val Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu 
        35                  40                  45              


Trp Leu Ala Leu Ile Tyr Trp Asn Asp Asp Lys Arg Tyr Ser Pro Ser 
    50                  55                  60                  


Leu Lys Ser Arg Leu Thr Ile Ala Lys Asp Thr Ser Lys Asn Gln Val 
65                  70                  75                  80  


Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 
                85                  90                  95      


Cys Ala Arg Met Gly Trp Asn Asp Pro His Met Val Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Leu Val Thr Val Ser Ser 
        115                 120     


<210>  64
<211>  119
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH of anti-NCR3 antibody

<400>  64

Glu Ile Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Phe Ser Ile Thr Thr Thr 
            20                  25                  30          


Gly Tyr Leu Ile Trp Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu 
        35                  40                  45              


Glu Trp Val Gly Tyr Ile Tyr Ser Ser Gly Ser Thr Ser Tyr Asn Pro 
    50                  55                  60                  


Ser Leu Lys Ser Arg Phe Thr Ile Ser Arg Asp Thr Ser Lys Asn Thr 
65                  70                  75                  80  


Phe Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr 
                85                  90                  95      


Tyr Cys Ala Arg Gly Asp Trp His Tyr Phe Asp Tyr Trp Gly Gln Gly 
            100                 105                 110         


Thr Met Val Thr Val Ser Ser 
        115                 


<210>  65
<211>  108
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL of anti-NCR3 antibody

<400>  65

Asp Ser Val Thr Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly 
1               5                   10                  15      


Gln Pro Ala Ser Ile Ser Cys Ser Gly Glu Lys Leu Ser Asp Lys Tyr 
            20                  25                  30          


Val His Trp Tyr Gln Gln Arg Pro Gly Gln Ser Pro Arg Met Leu Ile 
        35                  40                  45              


Tyr Glu Asn Asp Arg Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly 
    50                  55                  60                  


Ser Asn Ser Gly Asn Asp Ala Thr Leu Lys Ile Ser Arg Val Glu Ala 
65                  70                  75                  80  


Glu Asp Val Gly Val Tyr Phe Cys Gln Phe Trp Asp Ser Thr Asn Ser 
                85                  90                  95      


Ala Val Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
            100                 105             


